GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » 5-Year Sharpe Ratio

Microbix Biosystems (TSX:MBX) 5-Year Sharpe Ratio : 0.26 (As of Dec. 12, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2024-12-12), Microbix Biosystems's 5-Year Sharpe Ratio is 0.26.


Competitive Comparison of Microbix Biosystems's 5-Year Sharpe Ratio

For the Biotechnology subindustry, Microbix Biosystems's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's 5-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's 5-Year Sharpe Ratio falls into.



Microbix Biosystems 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.


Microbix Biosystems  (TSX:MBX) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Microbix Biosystems 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
Cameron Lionel Groome Director, Senior Officer
Bo Hollas Director
Steven Trevor Hagerman Senior Officer
Jennifer Anne Stewart Director
James Stuart Currie Senior Officer
Damian Klimaszewski Senior Officer
Kenneth Hughes Senior Officer
Anthony J. Giovinazzo Director
Martin Marino Director
Mark Adrian Luscher Senior Officer
Peter Martin Blecher Director